<DOC>
	<DOCNO>NCT00412984</DOCNO>
	<brief_summary>The trial seek determine apixaban , investigational anticoagulant ( blood-thinner ) effective standard therapy ( warfarin ) prevent stroke systemic embolism subject atrial fibrillation risk factor stroke .</brief_summary>
	<brief_title>Apixaban Prevention Stroke Subjects With Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Males female ≥ 18 yrs atrial fibrillation ( AF ) one follow risk factor stroke : Age ≥ 75 , previous stroke transient ischemic attack ( TIA ) Systemic Embolism ( SE ) Symptomatic congestive heart failure leave ventricular dysfunction leave ventricular ejection fraction ( LVEF ) ≤ 40 % Diabetes mellitus hypertension require pharmacological treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>